Keith A Sikora1, Alexei A Grom. 1. William S. Rowe Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory condition characterized by fever, lymphadenopathy, rash, arthritis, and serositis. Although the ultimate cause of this disorder remains elusive, recent work defining cytokine effector mechanisms has led to a new treatment paradigm for this condition. In this review, we describe the recent immunological reclassification of SJIA as an autoinflammatory disorder as well as detailing the dramatic changes in its treatment. RECENT FINDINGS: SJIA is an autoinflammatory disorder in which defects of innate immune system pathways lead to significant inflammation. Recent studies of the pathophysiology, as well as successful treatment trials, have established interleukin-1β (IL-1β) and IL-6 as key cytokines in the pathogenesis of this condition. As a result, their inhibition has become the centerpiece of the current SJIA treatment paradigm. SUMMARY: There has been a major shift away from the traditional treatments of SJIA towards therapeutics that inhibit IL-1β and IL-6. In fact, the IL-1 blocker anakinra is now regarded as standard of care for SJIA patients with systemic symptoms, while the IL-6 inhibitor tocilizumab shows great potential. Future research holds promise for the development of more efficient cytokine inhibition as well a more comprehensive knowledge of the innate cytokine networks in this disease.
PURPOSE OF REVIEW: Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory condition characterized by fever, lymphadenopathy, rash, arthritis, and serositis. Although the ultimate cause of this disorder remains elusive, recent work defining cytokine effector mechanisms has led to a new treatment paradigm for this condition. In this review, we describe the recent immunological reclassification of SJIA as an autoinflammatory disorder as well as detailing the dramatic changes in its treatment. RECENT FINDINGS: SJIA is an autoinflammatory disorder in which defects of innate immune system pathways lead to significant inflammation. Recent studies of the pathophysiology, as well as successful treatment trials, have established interleukin-1β (IL-1β) and IL-6 as key cytokines in the pathogenesis of this condition. As a result, their inhibition has become the centerpiece of the current SJIA treatment paradigm. SUMMARY: There has been a major shift away from the traditional treatments of SJIA towards therapeutics that inhibit IL-1β and IL-6. In fact, the IL-1 blocker anakinra is now regarded as standard of care for SJIA patients with systemic symptoms, while the IL-6 inhibitor tocilizumab shows great potential. Future research holds promise for the development of more efficient cytokine inhibition as well a more comprehensive knowledge of the innate cytokine networks in this disease.
Authors: Y Date; N Seki; S Kamizono; T Higuchi; T Hirata; K Miyata; M Ohkuni; O Tatsuzawa; S Yokota; K Joo; K Ueda; T Sasazuki; A Kimura; K Itoh; H Kato Journal: Arthritis Rheum Date: 1999-12
Authors: Keith M Hull; Nitza Shoham; Jae Jin Chae; Ivona Aksentijevich; Daniel L Kastner Journal: Curr Opin Rheumatol Date: 2003-01 Impact factor: 5.006
Authors: Emma M Ogilvie; Mark S Fife; Susan D Thompson; Natalie Twine; Monica Tsoras; Marta Moroldo; Sheila A Fisher; Cathryn M Lewis; Anne-Marie Prieur; David N Glass; Patricia Woo Journal: Arthritis Rheum Date: 2003-11
Authors: C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter Journal: J Exp Med Date: 1984-07-01 Impact factor: 14.307
Authors: Yanhong Cao; Yan Jiao; Lishi Wang; Yue Huang; Arnold Postlethwaite; John Stuart; Andy Kang; Robert W Williams; Weikuan Gu Journal: Int Immunopharmacol Date: 2012-03-14 Impact factor: 4.932
Authors: Iman I El Gazzar; Hanan M Fathy; Tamer A Gheita; Abeer M Nour El-Din; Enas Abdel Rasheed; Rasha H Bassyouni; Sanaa A Kenawy Journal: Clin Rheumatol Date: 2017-06-07 Impact factor: 2.980
Authors: M Bielak; E Husmann; N Weyandt; J-P Haas; B Hügle; G Horneff; U Neudorf; T Lutz; E Lilienthal; T Kallinich; K Tenbrock; R Berendes; T Niehues; H Wittkowski; E Weißbarth-Riedel; G Heubner; P Oommen; J Klotsche; Dirk Foell; E Lainka Journal: Pediatr Rheumatol Online J Date: 2018-04-05 Impact factor: 3.054